Key takeaways
- • Aetna commercial GLP-1 coverage splits sharply between T2D drugs (usually covered with PA) and weight-loss drugs (highly variable, often excluded by self-funded employers)
- • Self-funded ASO plans let employers exclude weight-loss drugs entirely — confirm with HR before assuming Wegovy or Zepbound is on your benefit
- • Prior authorization is the norm: expect to document T2D diagnosis or BMI ≥30 (or ≥27 with comorbidity) plus prior lifestyle intervention
- • Compounded semaglutide and tirzepatide are generally not reimbursed by Aetna; coverage applies to brand FDA-approved products only
- • Always pull your specific Aetna Pharmacy Drug List and verify tier, PA, and step-therapy with your current-year formulary
How Aetna (Commercial) approaches GLP-1 coverage
Aetna administers both fully-insured commercial plans (where Aetna sets the formulary) and Administrative Services Only (ASO) self-funded employer plans (where the employer customizes the benefit, including whether to cover weight-loss drugs at all). For T2D-indicated GLP-1s like Ozempic, Mounjaro, and Rybelsus, coverage is generally available on most Aetna commercial formularies when documented T2D criteria are met — but tier placement, step-therapy, and quantity limits vary; verify with your specific plan and current formulary. For weight-loss-indicated GLP-1s such as Wegovy and Zepbound, coverage is far less predictable: many large self-funded employers carve out anti-obesity meds, while others have added them with strict BMI + comorbidity prior-auth criteria. Members should pull their plan's specific Pharmacy Drug List and confirm tier plus utilization-management requirements before assuming coverage.
Statutory and structural notes
Commercial Aetna plans are not bound by the Medicare Part D weight-loss exclusion (Social Security Act §1860D-2(e)(2)(A)), so weight-loss GLP-1s are legally permissible on the formulary — but ACA essential health benefits do NOT require coverage of weight-loss drugs, giving employers full discretion. ERISA preempts most state-level coverage mandates for self-funded ASO plans, so state laws requiring obesity drug coverage typically do not apply. Fully-insured plans follow the issuing state's laws.
Typically considered for coverage
The list below reflects general patterns observed across Aetna (Commercial)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Ozempic for T2D when diabetes documentation criteria are met — verify tier and PA requirements with your specific plan and current formulary
- Mounjaro for T2D under standard diabetes PA criteria — verify with your specific plan and current formulary
- Rybelsus (oral semaglutide) for T2D on many formularies — verify with your specific plan and current formulary
- Wegovy for chronic weight management on plans whose employer has elected anti-obesity drug coverage, subject to BMI/comorbidity PA — verify with your specific plan and current formulary
- Zepbound for chronic weight management or, separately, for obstructive sleep apnea where the employer's plan covers it — verify with your specific plan and current formulary
- Trulicity and Victoza for T2D where still on formulary — verify with your specific plan and current formulary
Typically excluded
- Weight-loss GLP-1s under self-funded employer plans that have carved out anti-obesity medications
- Off-label use of T2D GLP-1s (Ozempic, Mounjaro) prescribed solely for weight loss without a T2D diagnosis
- Compounded semaglutide or tirzepatide from 503A/503B pharmacies — Aetna generally does not cover compounded GLP-1s
- GLP-1s prescribed outside FDA-approved indications and outside accepted compendia
- Saxenda on many newer formularies where it has been displaced by Wegovy/Zepbound — verify with your specific plan and current formulary
Prior authorization
Prior authorization is commonly required for GLP-1 medications under Aetna (Commercial) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
Request the denial letter and cited Clinical Policy Bulletin. File a Level 1 internal appeal (typically within 180 days) with a Letter of Medical Necessity documenting diagnosis, BMI, comorbidities, prior weight-loss attempts, and contraindications to alternatives. Escalate to Level 2 internal review, then external/independent (IRO) review under ACA. For ASO plans, confirm with HR whether a plan-design exclusion (not appealable) vs. medical-necessity denial is the barrier.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.